Xtalks Spotlight Interview: Strategies to Streamline Next-Gen AOCs & RDCs From Lead Candidate Design to Manufacture

In this Xtalks Spotlight, Abzena’s Dr. Stephen Verespy and Dr. Jeffrey C. Mocny, Ph.D. unpack development strategies that successfully move antibody-oligonucleotide (AOCs) and radionuclide-drug conjugates (RDCs) from lab to clinic. Watch the video below to hear what they had to share.

You May Also be Interested in